Zura Bio

Update in progress

ZURA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases in the United States. Its programs include Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody that neutralizes IL-17A and BAFF in one molecule, in Phase 2. It also develops Torudokimab (ZB-880), a fully human IgG4 mAb against IL-33 (Phase 1 completed), and Crebankitug (ZB-168), a fully human IgG1 mAb against IL-7 receptor alpha (Phase 1 completed). Founded in 2022, the company is headquartered in Henderson, Nevada.

Company score

Sentiment: 0.33; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive